Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)


CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2024 it awarded inducement grants to nine new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.

More:
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Related Posts